4
Changes in Ownership
CRISPR Therapeutics AG Filed Acc 0001209191-23-021911
Chief Executive Officer sold 25,000 shares at an average $44.46 ($1,111,504)
- Chief Executive Officer acquired 25,000 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
Table I: Non-derivative
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Kulkarni Samarth Chief Executive Officer | 2023-03-29 | Option exercise | +25,000 | $19.12 | $478,000 | 412,377 | D: show line 1 in the form |
| Kulkarni Samarth Chief Executive Officer | 2023-03-29 | Sale | −19,719 | $44.37 | $874,997 | 392,658 | D: show line 2 in the form |
| Kulkarni Samarth Chief Executive Officer | 2023-03-29 | Sale | −5,281 | $44.78 | $236,506 | 387,377 | D: show line 3 in the form |
| Open-market sales · 25,000 sh · avg $44.46 · $1,111,504 | |||||||
Table II: Derivative
| Insider | Date | Transaction | Shares | Price | Value | Exercise | Expires | Underlying | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|
| Kulkarni Samarth Chief Executive Officer | 2023-03-29 | Option exercise · Stock Option (Right to Buy) | −25,000 | 129,582 | D: show line 4 in the form |
Loading xslF345X04/doc4.xml…